세계의 척추 생물 제제 시장 : 규모 조사 및 예측, 제품별, 최종 용도별, 지역별 분석(2023-2030년)

Global Spine Biologics Market is valued at approximately USD 2.90 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5.08% over the forecast period 2023-2030. Spine biologics are biological materials used in treating spine-related conditions, promoting healing, tissue regeneration, or stabilization. They include bone grafts, bone morphogenetic proteins (BMPs), platelet-rich plasma (PRP), and mesenchymal stem cells (MSCs). These materials enhance healing, reduce complications, and improve outcomes in spinal surgeries by stimulating bone growth, tissue repair, and regeneration. Spine biologics play a crucial role in spine fusion surgery, addressing conditions like trauma, tumours, degenerative disc disease, and spinal cord injuries. The spinal biologics market growth is being driven by factors such as the increasing prevalence of spine disorders, subsequent increase in treatment rates, and the growing awareness regarding the benefits of biologics, including minimal postoperative time and faster recovery.

Along with this, spine biologics facilitate bone growth in various stages of spine fusion procedures, prompting their increased use with rising spinal fusion surgeries. The growing elderly population is a key driver for biologics demand, with spinal disorders like spinal stenosis prevalent among individuals over 50. Ageing induces structural spine changes, intensifying the risk of spinal impairments. The Journal of Spine Surgery (JSS) stated that Spinal deformities become more prevalent with age, affecting approximately 30% to 68% of the elderly population. Also, according to the Department of Economic and Social Affairs, in 2019, the world's population of people aged 65 and up totalled 703 million. Also, the number of elderly people is expected to increase to 1.5 billion by 2050. In addition to age-related conditions, the prevalence of other spine disorders, such as scoliosis, kyphosis, and intervertebral disc degeneration, is also rising. Consequently, the increase in the risk of spinal deformities among older individuals is expected to stimulate the demand for spine biologics as spinal fusion surgeries increase globally. Thus, the increase in the geriatric population is propelling the growth of the Spine Biologics Market during the estimated period. Moreover, the increase in advancements in bone grafting procedures, as well as the rising inclination towards minimally invasive procedures present various lucrative opportunities over the forecast years. However, reimbursement issues, high bone graft costs, and ethical concerns are hampering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Spine Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising inclination towards minimally invasive surgeries, and an increasing incidence of spine disorders such as disc-related issues, spinal stenosis, and spondylolisthesis. As per an article by the American Medical Association in May 2022, lumbar spinal stenosis is a prevalent issue, impacting approximately 11% of older adults in the U.S. Additionally, the presence of key industry players like Orthofix Holdings, Inc., Stryker, and NuVasive, Inc. throughout the U.S. is anticipated to bolster regional growth. Whereas Asia Pacific is expected to grow at the highest CAGR over the forecast years. The rise in the target patient population and growing awareness among patients and surgeons regarding the benefits of biologics are significantly propelling the market demand across the region. Also, the rise in the development of healthcare infrastructure, increasing healthcare spending, and a surge in the incidence of spine injuries are contributing to the region's market growth. Along with this, sedentary lifestyles and shifting behavioural patterns have led to an increased prevalence of obesity, further propelling market growth in the forecast period of 2023-2030.

Major market players included in this report are:

• Stryker
• NuVasive, Inc.
• Orthofix
• DePuy Synthes (Johnson & Johnson)
• Exactech, Inc.
• Zimmer Biomet
• Arthrex, Inc.
• Medtronic
• Organogenesis Inc.
• Kuros Biosciences.

Recent Developments in the Market:

• In October 2023, Orthofix Medical Inc., a leading supplier of spine and orthopaedic solutions, unveiled the full commercial launch and 510k clearance of OsteoCove, an advanced bioactive synthetic graft designed for orthopaedic and spine procedures. OsteoCove is offered in strip and putty configurations to meet varied surgical needs.
• In July 2023, Cerapedics Inc., a prominent bone graft provider, expanded its headquarters within the Denver metro area. This strategic expansion aims to bolster the company's diverse product portfolio, encompassing i-FACTOR bone grafts tailored for cervical spinal fusion procedures.
• In April 2023, PUR Biologics, a subsidiary of HippoFi, Inc., launched PURcore, a bioactive moldable synthetic designed specifically for spinal surgeries.

Global Spine Biologics Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Product, End-use, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent to up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters to detailed information about the crucial aspects such as driving factors & challenges that will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• Spinal Allografts
• Bone Graft Substitutes
• Cell-base Matrix

By End-use:

• Hospitals
• Ambulatory Surgical Centers

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1.Spine Biologics Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2.Spine Biologics Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3.Spine Biologics Market, by End-use, 2020-2030 (USD Billion)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Spine Biologics Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Spine Biologics Market Dynamics

• 3.1.Spine Biologics Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Increase in geriatric population
    • 3.1.1.2.Rising prevalence of spine disorders
  • 3.1.2.Market Challenges
    • 3.1.2.1.Reimbursement issues
    • 3.1.2.2.High cost of bone graft procedures
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Increase in advancements in bone grafting procedures
    • 3.1.3.2.Rising inclination towards minimally invasive procedures

Chapter 4.Global Spine Biologics Market Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economical
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Spine Biologics Market, by Product

• 5.1.Market Snapshot
• 5.2.Global Spine Biologics Market by Product, Performance - Potential Analysis
• 5.3.Global Spine Biologics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4.Spine Biologics Market, Sub Segment Analysis
  • 5.4.1.Spinal Allografts
  • 5.4.2.Bone Graft Substitutes
  • 5.4.3.Cell-base Matrix

Chapter 6.Global Spine Biologics Market, by End-use

• 6.1.Market Snapshot
• 6.2.Global Spine Biologics Market by End-use, Performance - Potential Analysis
• 6.3.Global Spine Biologics Market Estimates & Forecasts by End-use 2020-2030 (USD Billion)
• 6.4.Spine Biologics Market, Sub Segment Analysis
  • 6.4.1.Hospitals
  • 6.4.2.Ambulatory Surgical Centers

Chapter 7.Global Spine Biologics Market, Regional Analysis

• 7.1.Top Leading Countries
• 7.2.Top Emerging Countries
• 7.3.Spine Biologics Market, Regional Market Snapshot
• 7.4.North America Spine Biologics Market
  • 7.4.1.U.S. Spine Biologics Market
    • 7.4.1.1.Product breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2.End-use breakdown estimates & forecasts, 2020-2030
  • 7.4.2.Canada Spine Biologics Market
• 7.5.Europe Spine Biologics Market Snapshot
  • 7.5.1.U.K. Spine Biologics Market
  • 7.5.2.Germany Spine Biologics Market
  • 7.5.3.France Spine Biologics Market
  • 7.5.4.Spain Spine Biologics Market
  • 7.5.5.Italy Spine Biologics Market
  • 7.5.6.Rest of Europe Spine Biologics Market
• 7.6.Asia-Pacific Spine Biologics Market Snapshot
  • 7.6.1.China Spine Biologics Market
  • 7.6.2.India Spine Biologics Market
  • 7.6.3.Japan Spine Biologics Market
  • 7.6.4.Australia Spine Biologics Market
  • 7.6.5.South Korea Spine Biologics Market
  • 7.6.6.Rest of Asia Pacific Spine Biologics Market
• 7.7.Latin America Spine Biologics Market Snapshot
  • 7.7.1.Brazil Spine Biologics Market
  • 7.7.2.Mexico Spine Biologics Market
• 7.8.Middle East & Africa Spine Biologics Market
  • 7.8.1.Saudi Arabia Spine Biologics Market
  • 7.8.2.South Africa Spine Biologics Market
  • 7.8.3.Rest of Middle East & Africa Spine Biologics Market

Chapter 8.Competitive Intelligence

• 8.1.Key Company SWOT Analysis
• 8.2.Top Market Strategies
• 8.3.Company Profiles
  • 8.3.1.Stryker
    • 8.3.1.1.Key Information
    • 8.3.1.2.Overview
    • 8.3.1.3.Financial (Subject to Data Availability)
    • 8.3.1.4.Product Summary
    • 8.3.1.5.Recent Developments
  • 8.3.2.NuVasive, Inc.
  • 8.3.3.Orthofix
  • 8.3.4.DePuy Synthes (Johnson & Johnson)
  • 8.3.5.Exactech, Inc.
  • 8.3.6.Zimmer Biomet
  • 8.3.7.Arthrex, Inc.
  • 8.3.8.Medtronic
  • 8.3.9.Organogenesis Inc.
  • 8.3.10.Kuros Biosciences.

Chapter 9.Research Process

• 9.1.Research Process
  • 9.1.1.Data Mining
  • 9.1.2.Analysis
  • 9.1.3.Market Estimation
  • 9.1.4.Validation
  • 9.1.5.Publishing
• 9.2.Research Attributes
• 9.3.Research Assumption